Claims for Patent: 11,311,534

Summary for Patent: 11,311,534

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bio Ventures Ii LLC , Antecip Bioventures II LLC
Application Number:	US16/950,838
Patent Claims:	1. A method of treating treatment resistant depression, comprising administering a drug combination once a day or twice a day to a human being in need thereof for at least 8 consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan or an intermediate metabolizer of dextromethorphan, wherein the drug combination comprises: about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of a bupropion in the free base form or another salt form; and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in the free base form or another salt form; wherein the drug combination is orally administered in a single dosage form comprising the bupropion and the dextromethorphan as the only therapeutically active compounds, which provides immediate release of dextromethorphan and sustained release of bupropion; and wherein orally administering the dosage form results in the human being experiencing a therapeutic effect and is more effective in treating treatment resistant depression than orally administering the same amount of the dextromethorphan alone for the same number of consecutive days. 2. The method of claim 1, wherein after orally administering the dosage form, the human being experiences an improvement in a depressive symptom as compared to baseline. 3. The method of claim 1, wherein orally administering the dosage form is more effective in treating treatment resistant depression than orally administering a placebo. 4. The method of claim 1, wherein the dosage form is orally administered once daily. 5. The method of claim 1, wherein the dosage form is orally administered twice daily. 6. The method of claim 1, wherein the dosage form is orally administered for at least 14 consecutive days. 7. The method of claim 1, wherein the dosage form is orally administered for at least 30 consecutive days. 8. The method of claim 1, wherein the dosage form has a weight ratio of the dextromethorphan to the bupropion that is about 0.3 to about 0.5. 9. The method of claim 1, wherein the dosage form is orally administered once a day for 1 day and twice a day thereafter. 10. The method of claim 1, wherein the dosage form is orally administered once a day for 2 days and twice a day thereafter. 11. The method of claim 1, wherein the dosage form is orally administered once a day for 3 days and twice a day thereafter. 12. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing anxiety.